Cardiovascular

Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.

Two consultants who help stakeholders in value-based transitions say CMS is serious about an aggressive pace for payment reform.

The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August.

This would be the second group of procedures targeted for bundled payments in Medicare. Rules for hip and knee replacements went into effect in April in 67 markets.

Despite evidence and clinical guidelines that support intensive statin use in high-risk patients, very few eligible patients start treatment at recommended levels.

A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.

If the full FDA accepts the panel's narrow recommendation, the type 2 diabetes therapy could enjoy a preferred status above its rivals in the SGLT2 market.

The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.